American Society of Hirudotherapy

Bacterial symbiont and salivary peptide evolution in the context of leech phylogeny

Research article published in Parasitology (2011)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Antimicrobial ResistanceSalivary PharmacologySiddall ME et al. · Parasitology, 2011

Abstract

The evolutionary history of leeches is employed as a general framework for understanding more than merely the systematics of this charismatic group of annelid worms, and serves as a basis for understanding blood-feeding related correlates ranging from the specifics of gut-associated bacterial symbionts to salivary anticoagulant peptides. A variety of medicinal leech families were examined for intraluminal crop bacterial symbionts. Species of Aeromonas and Bacteroidetes were characterized with DNA gyrase B and 16S rDNA. Bacteroidetes isolates were found to be much more phylogenetically diverse and suggested stronger evidence of phylogenetic correlation than the gammaproteobacteria. Patterns that look like co-speciation with limited taxon sampling do not in the full context of phylogeny. Bioactive compounds that are expressed as gene products, like those in leech salivary glands, have 'passed the test' of evolutionary selection. We produced and bioinformatically mined salivary gland EST libraries across medicinal leech lineages to experimentally and statistically evaluate whether evolutionary selection on peptides can identify structure-function activities of known therapeutically relevant bioactive compounds like antithrombin, hirudin and antistasin. The combined information content of a well corroborated leech phylogeny and broad taxonomic coverage of expressed proteins leads to a rich understanding of evolution and function in leech history.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.S.
Indexed MeSH termsAeromonasAnimalsBacteriaBacteroidetesBiological EvolutionDNA GyraseDNA, BacterialDNA, RibosomalGammaproteobacteriaGastrointestinal TractHirudo medicinalisLeeches

Summary

The evolutionary history of leeches is employed as a general framework for understanding more than merely the systematics of this charismatic group of annelid worms, and serves as a basis for understanding blood-feeding related correlates ranging from the specifics of gut-associated bacterial symbionts to salivary a...

Why This Matters for Hirudotherapy

This study used leech evolutionary phylogeny as a framework to examine two blood-feeding correlates: crop-associated bacterial symbionts (Aeromonas and Bacteroidetes, characterized via DNA gyrase B and 16S rDNA) and salivary gland expressed peptides with therapeutic relevance, including antithrombin, hirudin, and antistasin. The authors bioinformatically mined EST libraries across medicinal leech lineages to test whether evolutionary selection can identify structure-function activities of these known bioactive compounds. For ASH, this work is relevant because it places the leech secretome's most celebrated anticoagulants in an explicitly evolutionary context, suggesting that comparative analysis across leech species can help illuminate why particular salivary peptides are effective. However, the study is fundamentally phylogenetic and bioinformatic—it reports no clinical data, no functional bioassays, and no therapeutic outcomes; it does not evaluate hirudotherapy efficacy or safety in any setting.

Citation

Bacterial symbiont and salivary peptide evolution in the context of leech phylogeny

Siddall ME et al. · Parasitology, 2011

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.